115 results
Page 4 of 6
8-K
EX-99.1
64z8mexb
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
EX-99.1
4nmhe5qf8 0ra2
1 Mar 21
Zai Lab Announces Financial Results
7:01am
10-K
EX-10.22
3n44ttyexbve 82zno
1 Mar 21
Annual report
12:00am
10-K
EX-10.20
wwr55dcl3eomyovs
1 Mar 21
Annual report
12:00am
10-K
EX-10.21
28hym1mpz72nghiwt
1 Mar 21
Annual report
12:00am
10-K
mc27wkfl3hif
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
hfmrstqzw22ni5pumc9
1 Mar 21
Annual report
12:00am
10-K
EX-10.33
642mlmme6krpizy2g1j
1 Mar 21
Annual report
12:00am
8-K
EX-99.1
c7rw921
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
EX-99.1
9ktd4ll1 v83j3
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
6-K
EX-99.1
osqseo7njv
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
s4dp90x3g26brhpe4tyc
28 Dec 20
Zai Lab and Cullinan Oncology Announce Strategic
7:30am
6-K
nwat9ysmr 3i0xqe9
9 Oct 20
Current report (foreign)
9:06am
6-K
EX-99.1
by6zwi cog
28 Sep 20
Zai Lab Announces Closing of Hong Kong Secondary Listing
7:52am
424B5
j3v qgw2j4s28xtn4v5n
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-99.1
51p5c dl8gkr
22 Sep 20
Zai Lab Announces Pricing of Hong Kong Secondary Listing
8:08am
6-K
EX-1.1
00jfc
21 Sep 20
Current report (foreign)
4:15pm
424B5
b00df4yap
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
xqbappq5s18zw3 92jxq
16 Sep 20
Zai Lab Launches Hong Kong Secondary Listing
7:18am
6-K
EX-99.1
5ffqcd974u 4nrk
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am